Erythropoietin and Myocardial Infarction

Clinical and Translational Science

Volumn 4, Issue 6, 2011, Pages 478-

  Sanchis Gomar, Fabian ^a,b   Martinez Bello, Vladimir E ^a,b   Lippi, Giuseppe ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b Instituto Universitario IVI INCLIVA   (Spain)

^c ACADEMIC HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; PROLACTIN; RECOMBINANT ERYTHROPOIETIN;

ARTERY BLOOD FLOW; BLOOD FLOW; BLOOD VISCOSITY; CARDIAC PATIENT; CARDIOVASCULAR RISK; DRUG EFFECT; ERYTHROCYTOSIS; HEART INFARCTION SIZE; HEMATOCRIT; HUMAN; LETTER; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ANIMALS; ERYTHROPOIETIN; HUMANS; MALE; MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 84855188336     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2011.00360.x     Document Type: Letter

References (5)

1. Kanashiro-Takeuchi RM, Takeuchi LM, Hatzistergos K, Quevedo H, Selem SM, Treuer AV, Premer C, Balkan W, Margitich I, Song Y, et al. Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction. Clin Transl Sci. 2011; 4: 168-174.
2. Greenberg G, Assali A, Vaknin-Assa H, Brosh D, Teplitsky I, Fuchs S, Battler A, Kornowski R, Lev EI. Hematocrit level as a marker of outcome in ST-segment elevation myocardial infarction. Am J Cardiol. 2010; 105: 435-440.
3. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol. 2011; 8: 502-512.
4. Najjar SS, Rao SV, Melloni C, Raman SV, Povsic TJ, Melton L, Barsness GW, Prather K, Heitner JF, Kilaru R, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011; 305: 1863-1872.
5. Bhatt DL. Evaluation of agents to reduce infarct size: it can be quite REVEALing. JAMA 2011; 305: 1908-1909.